Fairvalue-Calculator Fairvalue-Calculator
EN DE

Pentixapharm Holding (PTP) Fair Value & Analysis

Healthcare · DE · Market cap €62.0M

Price€2.01
Fair Value€0.9500
Upside-52.7%
Quality95/100
Evidence: Low Range €0.7100 – €1.42

Fair value as of: Jun 25, 2026

Analysis

Pentixapharm Holding (PTP) currently trades at €2.01, while our model-based Fair Value estimate is €0.9500 — implying the stock looks roughly 52.7% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Pentixapharm Holding AG, a clinical-stage biopharmaceutical company, develops radiopharmaceuticals. The company focuses on developing CXCR4 binding, peptide-based technology, which includes PentixaFor (PT-001), a tracer based on Gallium-68, used to diagnose and monitor the progress of various diseases, including hematological and solid tumors, as well as endocrine, cardiovascular, and immunological disorders; and PentixaTher (PT-002), a therapeutic radiopharmaceutical based on Yttrium-90 and Lutetium-177, for the treatment of leukemia, which is in Phase 1/2 study; and develops diagnosis for functional adrenal tumors, which is in Phase II study. It also develops anti-GlycoTarget antibodies to treat solid tumors. In addition, the company's PentixaFor is being developed as a diagnostic tool for primary hypertension, a cause of hypertension, which is in Phase III trial. Further, its pipeline products for oncology indications include PT-00X, GT-00X, GT-001, GT-002, GT-005, and GT-008. Pe…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Pentixapharm Holding (PTP) undervalued?
As of Jun 25, 2026, our model estimates a fair value of €0.9500 versus a price of €2.01 — about −53% (overvalued). Model-based estimate, not financial advice.
What is the fair value of PTP?
Our 21-model fair value for Pentixapharm Holding is €0.9500 (as of Jun 25, 2026), built from audited fundamentals. The current price is €2.01.
What is the quality score of PTP?
Pentixapharm Holding has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.